Table 1.
Patient characteristics
| Rt sided tumors (n=34) | Lt sided tumors (n=106) | p-value | MSS (%) (n=134) | MSI (%) (n=6) | p-value | |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 18 (52.9%) | 57 (53.8%) | 0.933 | 74 (55.2) | 1 (16.7) | 0.096 |
| Female | 16 (47.1%) | 49 (46.2%) | 60 (44.8) | 5 (83.3) | ||
| Age, years | ||||||
| ≤ 65 | 31 (91.2%) | 86 (81.1%) | 0.196 | 112 (83.6) | 5 (83.3) | 1.000 |
| 65 < | 3 (8.8%) | 20 (18.9%) | 22 (16.4) | 1 (16.7) | ||
| ECOG performance status | ||||||
| 0 | 5 (14.7%) | 10 (9.4%) | 0.360 | 15 (11.2) | 0 (0.0) | 1.000 |
| 1 | 29 (85.3%) | 96 (90.6%) | 119 (88.8) | 6 (100.0) | ||
| Primary site | - | - | ||||
| Left side colon | - | - | - | 102 (76.1%) | 4 (66.7%) | 0.633 |
| Right side colon | - | - | 32 (23.9%) | 2 (33.3%) | ||
| No. of metastatic sites | ||||||
| 1 | 20 (58.8%) | 53 (50.0%) | 0.432 | 71 (53.0) | 2 (33.3) | 0.426 |
| 1 < | 14 (41.2%) | 53 (30.0%) | 63 (47.0) | 4 (66.7) | ||
| Treatment line including bevacizumab | ||||||
| 1 | 18 (52.9%) | 64 (60.4%) | 0.549 | 79 (59.0) | 3 (50.0) | 0.692 |
| 1 < | 16 (47.1%) | 42 (39.6%) | 55 (41.) | 3 (50.0) | ||
| KRAS status | ||||||
| Wild | 17 (50.0%) | 68 (64.2%) | 0.161 | 79 (59.0) | 6 (100.0) | 0.081 |
| Mutant | 17 (50.0%) | 38 (35.8%) | 55 (41.0) | 0 (0.0) | ||
| BRAF status | ||||||
| Wild | 14 | 51 | 0.025 | 63 (47.4) | 2 (33.3) | 0.777 |
| Mutant | 5 | 3 | 8 (6.0) | 0 (0.0) | ||
| N.E. | 15 | 51 | 62 (46.6) | 4 (66.7) | ||
| MSI status | - | - | ||||
| MSI-H | 2 | 4 | 0.633 | - | - | - |
| MSS | 32 | 102 | - | - |
ECOG: Eastern Cooperative Oncology Group, MSS: microsatellite stable, MSI: microsatellite instability